



2023年3月期 第3四半期 決算参考資料
Financial Data for the 3rd quarter of FY2023
The FY2023, the year ending March 31, 2023
April 1, 2022 - March 31, 2023

1. 連結決算概要 / Consolidated Financial Summary	2
2. セグメント別情報 / Information by Business Segment	
(1) 医療分野 / Medical Business	3,4,5
ESD (Endoscopic Solutions Division)・TSD (Therapeutic Solutions Division)	
(2) その他 / Others	6
(3) 全社消去 / Corporate Expenses	6
(4) 非継続事業 (科学事業) / Discontinued Operation (Scientific Solutions Business)	7
3. 連結財政状態計算書 / Consolidated Statement of Financial Position	8
4. 連結キャッシュフロー計算書 / Consolidated Statement of Cash Flows	8
5. 従業員数 / Number of employees	8
6. 会社概要 / Corporate Outline	9

(本資料における留意点について)
(Notes regarding this material)

- ・本資料のうち、業績見通し等は、現在入手可能な情報による判断および仮定に基づいたものであり、判断や仮定に内在する不確定な要素および今後の事業運営や内外の状況変化等による変動可能性に照らし、実際の業績等が目標と大きく異なる可能性があります。
- ・また、これらの情報は、今後予告なしに変更されることがあります。従いまして、本情報及び資料の利用は、他の方法により入手された情報とも照合確認し、利用者の判断によって行ってくださいようお願い致します。
- ・本資料利用の結果生じたいかなる損害についても、当社は一切責任を負いません。
- ・2023年3月期より、治療機器事業のその他の治療領域に分類していた婦人科製品について、治療機器事業の泌尿器科に含めています。これに伴い、過去に開示した以下の数値も組み替えて表示しています。
サブセグメント別成長率：「2022年3月期第1四半期（3カ月）、第2四半期（3カ月）、第3四半期（3カ月）、第3四半期累計（9カ月）、第4四半期（3カ月）、通期」
- ・科学事業の譲渡に関する正式契約の締結に伴い、2023年3月期第2四半期連結会計期間より、科学事業を非継続事業に分類しています。これに伴い、過去に開示した以下の数値も組み替えて表示しています。**ただし、「第4四半期、通期」の数値は、監査前の数値となります。**
連結損益計算書：「2022年3月期第1四半期（3カ月）、第2四半期（3カ月）、第3四半期（3カ月）、第3四半期累計（9カ月）、第4四半期（3カ月）、通期」、「2023年3月期第1四半期（3カ月）」
連結キャッシュフロー計算書：「2022年3月期第3四半期（3カ月）、第3四半期累計（9カ月）、通期」
- ・2023年3月に非継続事業（エビデント）の全株式を譲渡する予定のため、非継続事業の2023年3月期最新見通しは、2023年2月末までの数値になります。
- ・This material contains forward-looking statements that reflect management's current views, plans, and expectations based on information available at the time of preparation. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, future business decisions, and other internal and external factors that may cause the Company's actual results, performance, achievements, or financial position to be materially different from any future results expressed or implied by these forward-looking statements.
- ・Additionally, this information is subject to change without notice. Accordingly, other information should be used in addition to this material when making investment decisions.
- ・Olympus Corporation assumes no responsibility for any damage resulting from the use of this material.
- ・From FY2023, Gynecology products classified in Other therapeutic areas in TSD are included in Urology in TSD. Accordingly, we restated figures for below accounting periods.
Growth Rate by Sub-segment: FY2022.Q1 (3M), FY2022.Q2 (3M), FY2022.Q3 (3M), FY2022.Q3 total (9M), FY2022.Q4 (3M), FY2022 (total)
- ・Following the conclusion of definitive agreement for divestiture of Scientific Solutions Business, Scientific Solutions Business is categorized as a discontinued operation, effective Q2 of FY2023. Accordingly, figures for below accounting periods are restated and **figures for the FY2022.Q4, and total are before the audit.**
Consolidated Statements of Profit or Loss: FY2022.Q1 (3M), FY2022.Q2 (3M), FY2022.Q3 (3M), FY2022.Q3 total (9M), FY2022.Q4 (3M), FY2022 (total), FY2023.Q1 (3M)
Consolidated Statement of cash flows: FY2022.Q3 (3M), FY2022.Q3 total (9M), FY2022 (total)
- ・Since all shares of discontinued operation (Evident) are scheduled to be transferred in March 2023, the latest forecast for discontinued operation for the fiscal year 2023 is based on the figures up to the end of February 2023.

1. 連結決算概要 / Consolidated Financial Summary

■ 連結損益計算書概要 / Summary of Consolidated Statements of Profit or Loss

百万円 (¥ million)

項目 Item	FY2022						FY2023					FY2023
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total forecast	As of Nov 11
売上高 Revenue	166,772	193,297	187,115	547,184	202,939	750,123	192,265	224,795	224,485	641,545	871,000	892,000
売上原価 Cost of sales	56,660	62,057	62,400	181,117	62,306	243,423	66,544	72,990	68,287	207,821	277,000	279,000
売上総利益 Gross profit	110,112	131,240	124,715	366,067	140,633	506,700	125,721	151,805	156,198	433,724	594,000	613,000
販売費及び一般管理費 S.G.A. expenses	84,485	84,445	90,182	259,112	98,398	357,510	96,018	102,517	107,550	306,085	411,000	413,500
その他の収益および費用等 Other income and expenses etc.	296	-2,056	-2,964	-4,724	1,722	-3,002	14,818	-206	321	14,933	15,000	12,500
営業利益 Operating profit	25,923	44,739	31,569	102,231	43,957	146,188	44,521	49,082	48,969	142,572	198,000	212,000
金融収益および費用 Finance income and costs	-488	-1,752	-2,981	-5,221	734	-4,487	-2,473	-1,809	1,080	-3,202	-1,000	-6,000
税引前利益 Profit before tax	25,435	42,987	28,588	97,010	44,691	141,701	42,048	47,273	50,049	139,370	197,000	206,000
法人所得税費用 Income taxes	7,053	2,937	4,053	14,043	17,031	31,074	14,158	5,637	13,956	33,751	48,000	49,000
継続事業からの当期利益 Profit from continuing operations	18,382	40,050	24,535	82,967	27,660	110,627	27,890	41,636	36,093	105,619	149,000	157,000
非継続事業からの当期利益(損失) Profit (loss) from discontinued operation	364	3,717	801	4,882	461	5,343	-2,968	382	5,336	2,750	227,000	230,000
当期利益(損失) Profit (loss)	18,746	43,767	25,336	87,849	28,121	115,970	24,922	42,018	41,429	108,369	376,000	387,000
親会社の所有者に帰属する当期利益(損失) Profit (loss) attributable to owners of parent	18,690	43,707	25,270	87,667	28,075	115,742	24,860	41,976	41,381	108,217	376,000	387,000

売上総利益率 Gross profit ratio	66.0%	67.9%	66.7%	66.9%	69.3%	67.5%	65.4%	67.5%	69.6%	67.6%	68.2%	68.7%
販管費率 S.G.A. ratio	50.7%	43.7%	48.2%	47.4%	48.5%	47.7%	49.9%	45.6%	47.9%	47.7%	47.2%	46.4%
営業利益率 Operating profit margin	15.5%	23.1%	16.9%	18.7%	21.7%	19.5%	23.2%	21.8%	21.8%	22.2%	22.7%	23.8%
継続事業からの当期利益率 Profit from continuing operations margin	11.0%	20.7%	13.1%	15.2%	13.6%	14.7%	14.5%	18.5%	16.1%	16.5%	17.1%	17.6%

EBITDA	39,962	59,189	46,008	145,159	58,880	204,039	60,287	65,899	65,493	191,679	263,000	277,000
EBITDAマージン EBITDA margin	24.0%	30.6%	24.6%	26.5%	29.0%	27.2%	31.4%	29.3%	29.2%	29.9%	30.2%	31.1%

* FY2023Q2より科学事業を非継続事業に分類しています。非継続事業からの利益は継続事業と区分し、「売上高」から「継続事業からの当期利益」までは継続事業の金額を表示しています。

FY2022Q4, totalの数値は監査前の数値となります。/

From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation. Accordingly, profit from discontinued operation is presented separately from the profit from continuing operations. From "revenue" to "profit from continuing operations" in the above table are amounts related to continuing operations only.

The figures for the FY2022Q4 and total are before the audit.

* 2023年3月に非継続事業（エビデント）の全株式を譲渡する予定のため、非継続事業の2023年3月期最新見通しは、2023年2月末までの数値になります /

Since all shares of discontinued operation (Evident) are scheduled to be transferred in March 2023, the latest forecast for discontinued operation for the fiscal year 2023 is based on the figures up to the end of February 2023.

■ 投資他 / Expenditures etc

百万円 (¥ million)

項目 Item	FY2022						FY2023					FY2023
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total forecast	As of Nov 11
減価償却費 Depreciation and amortization	14,039	14,450	14,439	42,928	14,923	57,851	15,766	16,817	16,524	49,107	65,000	65,000
資本的支出 Capital expenditures	15,721	16,283	17,074	49,078	17,115	66,193	11,429	18,066	19,409	48,904	71,000	64,000
研究開発支出 R&D expenditures	18,451	17,633	19,256	55,340	19,850	75,190	16,965	19,127	15,333	51,425	75,000	80,000
開発費資産化 Capitalization of R&D expenditures	3,199	3,271	3,169	9,639	1,969	11,608	1,655	3,908	3,268	8,831	14,000	14,000

* 上表の数値は継続事業の金額を表示しています。/ Amounts in the above table are related to continuing operations only.

■ 為替 / Foreign exchange

項目 Item	FY2022						FY2023					FY2023
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total forecast	As of Nov 11
円/USD (期中平均レート) Yen/U.S. dollar (Average rate)	109.49	110.11	113.71	111.10	116.20	112.38	129.57	138.37	141.59	136.51	135	140
円/EUR (期中平均レート) Yen/Euro (Average rate)	131.96	129.84	130.07	130.62	130.39	130.56	138.12	139.34	144.30	140.59	140	139
円/CNY (期中平均レート) Yen/Renminyuan (Average rate)	16.96	17.02	17.78	17.25	18.29	17.51	19.58	20.19	19.87	19.88	19.7	20.1

売上高に対する為替影響額 FX Impact on revenue	-	-	-	-	-	-	19,482	30,228	29,050	78,760	-	-
営業利益に対する為替影響額 FX Impact on operating profit	-	-	-	-	-	-	7,934	13,168	12,989	34,091	-	-

* 上表の数値は継続事業の金額を表示しています。/ Amounts in the above table are related to continuing operations only.

■ 為替感応度 (年間) / Foreign exchange sensitivity (Annual basis) 億円 (¥ 100 million)

項目 Item	売上高 Revenue	営業利益 Operating profit
ドル (1円あたり) U.S. dollar (Per 1JPY)	25	11
ユーロ (1円あたり) Euro (Per 1JPY)	16	7
人民元 (1円あたり) Renminyuan (Per 1JPY)	60	39

* 上表の数値は継続事業の金額を表示しています。/ Amounts in the above table are related to continuing operations only.

2. セグメント別情報 / Information by Business Segment

(1) 医療分野 / Medical Business

■ ESD 損益 / Revenue and Operating profit of ESD

百万円 (¥ million)

項目 Item	FY2022						FY2023					FY2023 As of Nov 11
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total forecast	
売上高 Revenue	100,014	120,551	113,136	333,701	127,846	461,547	116,857	141,615	140,518	398,990	542,000	552,000
営業利益 Operating profit	22,654	38,991	29,955	91,600	41,604	133,204	24,834	44,065	41,804	110,703	163,500	173,500
その他の損益 Other income and expenses	-2,153	-952	-887	-3,992	1,097	-2,895	-1,179	-236	-908	-2,323	-	-
営業利益率 Operating profit margin	22.7%	32.3%	26.5%	27.4%	32.5%	28.9%	21.3%	31.1%	29.7%	27.7%	30.2%	31.4%

売上高対前年比 Revenue (YoY)							16.8%	17.5%	24.2%	19.6%	17.4%
営業利益対前年比 Operating profit (YoY)							9.6%	13.0%	39.6%	20.9%	22.7%

■ TSD 損益 / Revenue and Operating profit of TSD

百万円 (¥ million)

項目 Item	FY2022						FY2023					FY2023 As of Nov 11
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total forecast	
売上高 Revenue	63,646	69,455	70,613	203,714	71,872	275,586	72,365	80,570	81,007	233,942	318,000	329,000
営業利益 Operating profit	14,072	16,190	13,583	43,845	16,981	60,826	13,357	16,431	18,328	48,116	69,500	75,000
その他の損益 Other income and expenses	2,538	-422	-833	1,283	1,727	3,010	-242	116	1,288	1,162	-	-
営業利益率 Operating profit margin	22.1%	23.3%	19.2%	21.5%	23.6%	22.1%	18.5%	20.4%	22.6%	20.6%	21.9%	22.8%

売上高対前年比 Revenue (YoY)							13.7%	16.0%	14.7%	14.8%	15.4%
営業利益対前年比 Operating profit (YoY)							-5.1%	1.5%	34.9%	9.7%	14.3%

■ 医療分野 損益 / Revenue and Operating profit of Medical Business

百万円 (¥ million)

項目 Item	FY2022						FY2023					FY2023 As of Nov 11
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total forecast	
売上高 Revenue	163,660	190,006	183,749	537,415	199,718	737,133	189,222	222,185	221,525	632,932	860,000	881,000
営業利益 Operating profit	36,726	55,181	43,538	135,445	58,585	194,030	38,191	60,496	60,132	158,819	233,000	248,500
その他の損益 Other income and expenses	385	-1,374	-1,720	-2,709	2,824	115	-1,421	-120	380	-1,161	-	-
営業利益率 Operating profit margin	22.4%	29.0%	23.7%	25.2%	29.3%	26.3%	20.2%	27.2%	27.1%	25.1%	27.1%	28.2%

売上高対前年比 Revenue (YoY)							15.6%	16.9%	20.6%	17.8%	16.7%
営業利益対前年比 Operating profit (YoY)							4.0%	9.6%	38.1%	17.3%	20.1%

■ ESD 投資他 / Expenditures etc of ESD

百万円 (¥ million)

項目 Item	FY2022						FY2023				
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total
減価償却費 Depreciation and amortization	7,983	8,278	8,579	24,840	8,683	33,523	9,167	9,947	10,157	29,271	-
資本的支出 Capital expenditures	10,504	8,782	10,267	29,553	10,884	40,437	6,749	11,393	11,996	30,138	-
研究開発支出 R&D expenditures	9,177	9,033	10,687	28,897	10,424	39,321	8,861	10,800	8,498	28,159	-

■ TSD 投資他 / Expenditures etc of TSD

百万円 (¥ million)

項目 Item	FY2022						FY2023				
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total
減価償却費 Depreciation and amortization	3,877	4,089	4,472	12,438	4,497	16,935	4,793	4,846	4,874	14,513	-
資本的支出 Capital expenditures	2,835	4,213	5,457	12,505	3,838	16,343	3,119	3,355	3,849	10,323	-
研究開発支出 R&D expenditures	4,780	5,061	5,379	15,220	5,477	20,697	5,198	5,502	4,722	15,422	-

■ 医療分野 投資他 / Expenditures etc of Medical Business

百万円 (¥ million)

項目 Item	FY2022						FY2023				
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total
減価償却費 Depreciation and amortization	11,860	12,367	13,051	37,278	13,180	50,458	13,960	14,793	15,031	43,784	-
資本的支出 Capital expenditures	13,339	12,995	15,724	42,058	14,722	56,780	9,868	14,748	15,845	40,461	-
研究開発支出 R&D expenditures	13,957	14,094	16,066	44,117	15,901	60,018	14,059	16,302	13,220	43,581	-

■ ESD 地域別売上高 / Revenue by Region of ESD

百万円 (¥ million)

項目 Item	FY2022						FY2023				
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total
日本 Japan	13,543	17,722	15,572	46,837	19,071	65,908	14,914	18,059	15,318	48,291	-
北米 North America	37,353	39,444	38,449	115,246	45,820	161,066	44,432	50,948	50,854	146,234	-
欧州 Europe	25,060	29,493	31,213	85,766	31,279	117,045	30,993	31,034	34,968	96,995	-
中国 China	13,717	21,118	14,410	49,245	19,054	68,299	12,388	24,100	22,625	59,113	-
アジア・オセアニア Asia and Oceania	8,590	10,395	10,473	29,458	10,204	39,662	11,195	13,448	13,186	37,829	-
その他 Others	1,751	2,379	3,019	7,149	2,418	9,567	2,935	4,026	3,567	10,528	-
合計 Total	100,014	120,551	113,136	333,701	127,846	461,547	116,857	141,615	140,518	398,990	-

■ TSD 地域別売上高 / Revenue by Region of TSD

百万円 (¥ million)

項目 Item	FY2022						FY2023				
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total
日本 Japan	10,213	11,946	11,868	34,027	10,961	44,988	10,781	11,654	11,698	34,133	-
北米 North America	23,945	25,167	25,201	74,313	25,761	100,074	28,654	31,575	32,173	92,402	-
欧州 Europe	16,542	16,277	20,148	52,967	19,822	72,789	19,261	18,830	21,708	59,800	-
中国 China	6,952	9,778	6,733	23,463	9,188	32,651	6,836	10,160	7,451	24,447	-
アジア・オセアニア Asia and Oceania	5,187	5,249	5,529	15,965	5,184	21,149	5,469	6,832	6,513	18,814	-
その他 Others	807	1,038	1,134	2,979	956	3,935	1,364	1,519	1,464	4,346	-
合計 Total	63,646	69,455	70,613	203,714	71,872	275,586	72,365	80,570	81,007	233,942	-

■ 医療分野 地域別売上高 / Revenue by Region of Medical Business

百万円 (¥ million)

項目 Item	FY2022						FY2023				
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total
日本 Japan	23,756	29,668	27,440	80,864	30,032	110,896	25,695	29,713	27,016	82,424	-
北米 North America	61,298	64,611	63,650	189,559	71,581	261,140	73,086	82,523	83,027	238,636	-
欧州 Europe	41,602	45,770	51,361	138,733	51,101	189,834	50,254	49,864	56,676	156,795	-
中国 China	20,669	30,896	21,143	72,708	28,242	100,950	19,224	34,260	30,076	83,560	-
アジア・オセアニア Asia and Oceania	13,777	15,644	16,002	45,423	15,388	60,811	16,664	20,280	19,699	56,643	-
その他 Others	2,558	3,417	4,153	10,128	3,374	13,502	4,299	5,545	5,031	14,874	-
合計 Total	163,660	190,006	183,749	537,415	199,718	737,133	189,222	222,185	221,525	632,932	-

■ ESDサブセグメント別売上占有率 / Sub-segment Sales Ratio within ESD

(FY2023 Q3 Total)

消化器内視鏡 Gastrointestinal Endoscope	外科内視鏡 Surgical Endoscope	医療サービス Medical Service
約 Approx. 55%	約 Approx. 10%	約 Approx. 30%

■ TSDサブセグメント別売上占有率 / Sub-segment Sales Ratio within TSD

(FY2023 Q3 Total)

消化器科 (処置具) GI-Endotherapy	泌尿器科 Urology	呼吸器科 Respiratory	その他の治療領域 Other Therapeutic Areas
約 Approx. 30%	約 Approx. 35%	約 Approx. 15%	約 Approx. 20%

* 四捨五入のため、合計値が100%にならないことがあります。 / Due to rounding, the total may not add up to 100%.

■地域別成長率（為替影響調整後） /

Growth Rate by Region (After Foreign Exchange Adjustment)

項目 Item	FY2022							FY2023					
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total		
ESD	日本 Japan	38% (38%)	15% (15%)	8% (8%)	18% (18%)	-7% (-7%)	10% (10%)	10% (10%)	2% (2%)	-2% (-2%)	3% (3%)		
	北米 North America	42% (38%)	26% (22%)	9% (-1%)	24% (18%)	16% (6%)	22% (14%)	19% (0%)	29% (3%)	32% (7%)	27% (3%)		
	欧州 Europe	31% (18%)	22% (15%)	7% (0%)	18% (10%)	9% (5%)	16% (9%)	24% (14%)	5% (-6%)	12% (-1%)	13% (2%)		
	中国 China	21% (8%)	29% (16%)	-11% (-21%)	12% (0%)	18% (5%)	14% (2%)	-10% (-23%)	14% (-4%)	57% (38%)	20% (3%)		
	アジア・オセアニア Asia and Oceania	33% (21%)	26% (20%)	25% (20%)	28% (20%)	7% (4%)	22% (16%)	30% (21%)	29% (16%)	26% (14%)	28% (17%)		
	分野計 Total	35% (27%)	24% (18%)	7% (0%)	21% (14%)	9% (3%)	17% (10%)	17% (5%)	17% (1%)	24% (8%)	20% (5%)		
	TSD	日本 Japan	19% (19%)	15% (15%)	6% (6%)	13% (13%)	-4% (-4%)	8% (8%)	6% (6%)	-2% (-2%)	-1% (-1%)	0% (0%)	
		北米 North America	79% (75%)	20% (15%)	19% (9%)	34% (27%)	11% (1%)	27% (19%)	20% (1%)	25% (0%)	28% (3%)	24% (1%)	
		欧州 Europe	56% (40%)	13% (7%)	23% (15%)	28% (19%)	12% (8%)	23% (15%)	16% (9%)	16% (5%)	8% (-4%)	13% (3%)	
		中国 China	12% (1%)	29% (16%)	-11% (-22%)	10% (-2%)	-4% (-15%)	5% (-6%)	-2% (-16%)	4% (-13%)	11% (-3%)	4% (-11%)	
アジア・オセアニア Asia and Oceania		40% (26%)	12% (6%)	11% (6%)	19% (12%)	6% (4%)	16% (10%)	5% (-2%)	30% (18%)	18% (8%)	18% (8%)		
分野計 Total		48% (40%)	18% (13%)	13% (6%)	24% (17%)	6% (0%)	19% (12%)	14% (2%)	16% (1%)	15% (0%)	15% (1%)		
医療分野 Medical Business		日本 Japan	29% (29%)	15% (15%)	7% (7%)	16% (16%)	-6% (-6%)	9% (9%)	8% (8%)	0% (0%)	-2% (-2%)	2% (2%)	
		北米 North America	54% (50%)	23% (19%)	12% (3%)	27% (21%)	14% (4%)	24% (16%)	19% (1%)	28% (2%)	30% (5%)	26% (3%)	
		欧州 Europe	40% (26%)	19% (12%)	13% (5%)	22% (13%)	10% (6%)	18% (11%)	21% (12%)	9% (-2%)	10% (-2%)	13% (2%)	
		中国 China	18% (6%)	29% (16%)	-11% (-21%)	11% (0%)	10% (-2%)	11% (-1%)	-7% (-20%)	11% (-7%)	42% (25%)	15% (-2%)	
	アジア・オセアニア Asia and Oceania	35% (23%)	21% (15%)	20% (15%)	25% (17%)	6% (4%)	20% (14%)	21% (12%)	30% (17%)	23% (12%)	25% (14%)		
	分野計 Total	40% (32%)	22% (16%)	10% (2%)	22% (15%)	8% (2%)	18% (11%)	16% (4%)	17% (1%)	21% (5%)	18% (3%)		

* () は為替影響調整後の成長率です。 / () :Growth rate after foreign exchange adjustment

■サブセグメント別成長率（為替影響調整後） /

Growth Rate by Sub-segment (After Foreign Exchange Adjustment)

項目 Item	FY2022							FY2023					
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total		
ESD	消化器内視鏡 Gastrointestinal	47% (38%)	30% (23%)	4% (-3%)	24% (16%)	6% (0%)	18% (11%)	18% (5%)	17% (1%)	27% (10%)	20% (5%)		
	外科内視鏡 Surgical Endoscope	34% (28%)	22% (17%)	17% (9%)	23% (17%)	5% (0%)	17% (11%)	11% (-1%)	4% (-10%)	7% (-7%)	7% (-7%)		
	医療サービス Medical Service	19% (11%)	16% (10%)	10% (2%)	14% (8%)	18% (11%)	15% (9%)	17% (5%)	25% (8%)	27% (10%)	23% (8%)		
	分野計 Total	35% (27%)	24% (18%)	7% (0%)	21% (14%)	9% (3%)	17% (10%)	17% (5%)	17% (1%)	24% (8%)	20% (5%)		
	TSD	消化器科（処置具） GI-Endotherapy	40% (32%)	13% (9%)	11% (6%)	20% (14%)	4% (0%)	15% (10%)	14% (5%)	15% (3%)	12% (2%)	13% (3%)	
		泌尿器科 Urology	68% (59%)	20% (14%)	16% (7%)	30% (22%)	9% (1%)	24% (16%)	18% (4%)	24% (4%)	22% (3%)	22% (4%)	
		呼吸器科 Respiratory	42% (33%)	36% (29%)	13% (4%)	29% (21%)	-1% (-7%)	19% (12%)	7% (-5%)	9% (-7%)	14% (-2%)	10% (-5%)	
その他の治療領域 Other Therapeutic Areas		41% (32%)	12% (7%)	13% (7%)	20% (13%)	9% (4%)	17% (11%)	12% (2%)	12% (-1%)	8% (-5%)	11% (-1%)		
分野計 Total		48% (40%)	18% (13%)	13% (6%)	24% (17%)	6% (0%)	19% (12%)	14% (2%)	16% (1%)	15% (0%)	15% (1%)		

* () は為替影響調整後の成長率です。 / () :Growth rate after foreign exchange adjustment

* FY2023より、治療機器事業のその他の治療領域に分類していた婦人科製品について、治療機器事業の泌尿器科に含めています。

これに伴い、FY2022Q1、Q2、Q3、Q3 total、Q4、totalの数値も組み替えて表示しています。 /

From FY2023, Gynecology products classified in Other therapeutic areas in TSD are included in Urology in TSD. Accordingly, we restated figures for FY2022Q1, Q2, Q3, Q3 total, Q4, and total.

2. セグメント別情報 / Information by Business Segment

(2) その他 / Others

■ 損益 / Revenue and Operating profit

百万円 (¥ million)

項目 Item	FY2022						FY2023					FY2023
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total forecast	As of Nov 11
売上高 Revenue	3,112	3,291	3,366	9,769	3,221	12,990	3,043	2,610	2,960	8,613	11,000	11,000
営業損益 Operating profit (loss)	-563	-573	-344	-1,480	-537	-2,017	-296	-492	-129	-917	-1,500	-1,500
その他の損益 Other income and expenses	31	-406	17	-358	-248	-606	0	-8	-26	-34	-	-
営業利益率 Operating profit margin	-	-	-	-	-	-	-	-	-	-	-	-

売上高対前年比 Revenue (YoY)	/	/	/	/	/	/	-2.2%	-20.7%	-12.1%	-11.8%	-15.3%
営業利益対前年比 Operating profit (YoY)	/	/	/	/	/	/	-	-	-	-	-

* FY2023Q2より科学事業を非継続事業に分類したことに伴い、FY2022Q1、Q2、Q3、Q3 total、Q4、total、FY2023Q1の数値も組み替えて表示しています。FY2022Q4、totalの数値は監査前の数値となります。/

From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2022Q1, Q2, Q3, Q3 total, Q4, total, and FY2023Q1.

The figures for the FY2022Q4 and total are before the audit.

■ 地域別売上高 / Revenue by Region

百万円 (¥ million)

項目 Item	FY2022						FY2023				
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total
日本 Japan	1,896	2,162	2,096	6,154	1,776	7,930	1,603	1,364	1,357	4,324	-
北米 North America	61	38	44	143	68	211	40	34	30	104	-
欧州 Europe	1,091	992	1,152	3,235	1,297	4,532	1,321	1,103	1,419	3,843	-
中国 China	14	2	11	27	-3	24	7	14	10	31	-
アジア・オセアニア Asia and Oceania	50	97	63	210	83	293	72	95	144	311	-
その他 Others	-	-	-	-	-	-	-	-	-	-	-
合計 Total	3,112	3,291	3,366	9,769	3,221	12,990	3,043	2,610	2,960	8,613	-

* FY2023Q2より科学事業を非継続事業に分類したことに伴い、FY2022Q1、Q2、Q3、Q3 total、Q4、total、FY2023Q1の数値も組み替えて表示しています。FY2022Q4、totalの数値は監査前の数値となります。/

From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2022Q1, Q2, Q3, Q3 total, Q4, total, and FY2023Q1.

The figures for the FY2022Q4 and total are before the audit.

(3) 全社消去 / Corporate expenses

■ 損益 / Revenue and Operating profit

百万円 (¥ million)

項目 Item	FY2022						FY2023					FY2023
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total forecast	As of Nov 11
売上高 Revenue	-	-	-	-	-	-	-	-	-	-	-	-
営業損益 Operating profit (loss)	-10,240	-9,869	-11,625	-31,734	-14,091	-45,825	6,626	-10,922	-11,034	-15,330	-33,500	-35,000
その他の損益 Other income and expenses	-155	-640	-1,439	-2,234	-1,769	-4,003	16,202	-412	-152	15,638	-	-

* FY2023Q2より科学事業を非継続事業に分類したことに伴い、減価償却費及び資本的支出のFY2022Q1、Q2、Q3、Q3 total、Q4、totalの数値も組み替えて表示しています。/

From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2022Q1, Q2, Q3, Q3 total, Q4, total, and FY2023Q1.

The figures for the FY2022Q4 and total are before the audit.

■ 投資他 (その他・全社消去) / Expenditures etc (Others, Corporate expenses)

百万円 (¥ million)

項目 Item	FY2022						FY2023				
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total
減価償却費 Depreciation and amortization	2,179	2,083	1,388	5,650	1,743	7,393	1,806	2,024	1,493	5,323	-
資本的支出 Capital expenditures	2,382	3,288	1,350	7,020	2,393	9,413	1,561	3,318	3,564	8,443	-
研究開発支出 R&D expenditures	4,494	3,539	3,190	11,223	3,949	15,172	2,906	2,825	2,113	7,844	-

* FY2023Q2より科学事業を非継続事業に分類したことに伴い、減価償却費及び資本的支出のFY2022Q1、Q2、Q3、Q3 total、Q4、totalの数値も組み替えて表示しています。/

From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation.

Accordingly, we restated figures for "depreciation and amortization" and "capital expenditures" for FY2022Q1, Q2, Q3, Q3 total, Q4, and total.

2. セグメント別情報 / Information by Business Segment

(4) 非継続事業（科学事業） / Discontinued Operation (Scientific Solutions Business)

■ 損益 / Revenue and Operating profit

百万円 (¥ million)

項目 Item	FY2022						FY2023					FY2023
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total forecast	As of Nov 11
売上高 Revenue	24,745	28,245	29,583	82,573	36,171	118,744	21,795	30,949	38,267	91,011	119,000	95,000
営業損益 Operating profit (loss)	1,689	3,905	1,085	6,679	1,031	7,710	-3,745	-1,138	6,364	1,481	350,000	354,000
その他の損益 Other income and expenses	-203	-580	-3,803	-4,586	-4,810	-9,396	-2,336	-2,609	-3,309	-8,254	-	-
営業利益率 Operating profit margin	6.8%	13.8%	3.7%	8.1%	2.9%	6.5%	-	-	16.6%	1.6%	294.1%	372.6%

売上高対前年比 Revenue (YoY)							-11.9%	9.6%	29.4%	10.2%	0.2%
営業利益対前年比 Operating profit (YoY)							-	-	486.5%	-77.8%	4439.6%

* FY2023Q2より科学事業を非継続事業に分類したことに伴い、FY2022Q1、Q2、Q3、Q3 total、Q4、total、FY2023Q1の数値も組み替えて表示しています。FY2022Q4、totalの数値は監査前の数値となります。/

From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2022Q1, Q2, Q3, Q3 total, Q4, total, and FY2023Q1.

The figures for the FY2022Q4 and total are before the audit.

* 2023年3月に非継続事業（エビデント）の全株式を譲渡する予定のため、非継続事業の2023年3月期最新見通しは、2023年2月末までの数値になります /

Since all shares of discontinued operation (Evident) are scheduled to be transferred in March 2023, the latest forecast for discontinued operation for the fiscal year 2023 is based on the figures up to the end of February 2023.

■ 投資他 / Expenditures etc

百万円 (¥ million)

項目 Item	FY2022						FY2023				
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total
減価償却費 Depreciation and amortization	1,700	1,686	1,679	5,065	1,699	6,764	1,920	1,315	-29	3,206	-
資本的支出 Capital expenditures	1,173	1,853	2,436	5,462	3,848	9,310	4,691	2,325	2,517	9,533	-
研究開発支出 R&D expenditures	1,971	2,705	2,513	7,189	2,893	10,082	2,224	2,578	2,786	7,588	-

* FY2023Q2より科学事業を非継続事業に分類したことに伴い、減価償却費及び資本的支出のFY2022Q1、Q2、Q3、Q3 total、Q4、totalの数値も組み替えて表示しています。/

From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation.

Accordingly, we restated figures for "depreciation and amortization" and "capital expenditures" for FY2022Q1, Q2, Q3, Q3 total, Q4, and total.

■ 地域別売上高 / Revenue by Region

百万円 (¥ million)

項目 Item	FY2022						FY2023				
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total
日本 Japan	2,442	4,306	3,287	10,035	6,336	16,371	1,915	3,186	2,881	7,982	-
北米 North America	6,920	7,543	8,216	22,679	9,411	32,090	7,505	9,079	10,913	27,497	-
欧州 Europe	4,413	5,378	6,190	15,982	7,511	23,492	4,202	4,057	7,645	15,903	-
中国 China	5,509	5,514	6,080	17,103	7,329	24,432	1,756	8,298	9,110	19,164	-
アジア・オセアニア Asia and Oceania	3,860	3,808	4,070	11,738	4,642	16,380	4,930	4,046	5,113	14,089	-
その他 Others	1,601	1,696	1,740	5,036	942	5,979	1,487	2,283	2,605	6,376	-
合計 Total	24,745	28,245	29,583	82,573	36,171	118,744	21,795	30,949	38,267	91,011	-

* FY2023Q2より科学事業を非継続事業に分類したことに伴い、FY2022Q1、Q2、Q3、Q3 total、Q4、total、FY2023Q1の数値も組み替えて表示しています。FY2022Q4、totalの数値は監査前の数値となります。/

From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2022Q1, Q2, Q3, Q3 total, Q4, total, and FY2023Q1.

The figures for the FY2022Q4 and total are before the audit.

■ サブセグメント別売上占有率 / Sub-segment Sales Ratio (FY2023 Q3 Total)

ライフサイエンス Life Science	約 40%	産業 Industrial	約 60%
Approx.	40%	Approx.	60%

■ サブセグメント別成長率（為替影響調整後） /

Growth Rate by Sub-segment (After Foreign Exchange Adjustment)

項目 Item	FY2022						FY2023				
	Q1	Q2	Q3	Q3 Total	Q4	Total	Q1	Q2	Q3	Q3 Total	Total
ライフサイエンス Life Science	-	-	-	-	-	-	-	-4%	26%	4%	-
産業 Industrial	-	-	-	-	-	-	-	19%	32%	14%	-
分野計 Total	-	-	-	-	-	-	-	10%	29%	10%	-
								(-6%)	(12%)	(-4%)	

* () は為替影響調整後の成長率です。/ () :Growth rate after foreign exchange adjustment

3. 連結財政状態計算書 / Consolidated statement of financial position

百万円 (¥ million)

項目 Item	FY2022					FY2023			
	As of Jun 30	As of Sep 30	As of Dec 31	As of Dec 31	As of Mar 31	As of Jun 30	As of Sep 30	As of Dec 31	As of Mar 31
資産 Assets	1,144,606	1,185,302	1,292,967	1,292,967	1,357,999	1,433,466	1,486,123	1,392,608	-
流動資産 Current assets	513,399	552,314	657,331	657,331	694,605	723,090	791,579	722,541	-
現金及び現金同等物 Cash and cash equivalents	168,713	193,435	275,090	275,090	302,572	286,412	255,765	175,748	-
棚卸資産 Inventories	164,057	166,047	166,958	166,958	167,368	186,875	171,182	170,912	-
売却目的で保有する資産 Assets held for sale	435	-	-	-	4,685	-	122,512	132,273	-
その他 Others	180,194	192,832	215,283	215,283	219,980	249,803	242,120	243,608	-
非流動資産 Non-current assets	631,207	632,988	635,636	635,636	663,394	710,376	694,544	670,067	-
負債 Liabilities	743,228	738,071	812,673	812,673	846,637	851,311	842,027	787,020	-
流動負債 Current liabilities	282,670	288,236	333,287	333,287	376,251	362,857	359,737	355,252	-
売却目的で保有する資産に直接関連する負債 Liabilities directly associated with assets held for sale	1,056	-	-	-	-	-	34,404	32,799	-
非流動負債 Non-current liabilities	460,558	449,835	479,386	479,386	470,386	488,454	482,290	431,768	-
資本 Equity	401,378	447,231	480,294	480,294	511,362	582,155	644,096	605,588	-
親会社の所有者に帰属する持分 Total equity attributable to owners of parent	400,356	446,149	479,146	479,146	510,168	581,125	643,024	604,468	-
その他 Others	1,022	1,082	1,148	1,148	1,194	1,030	1,072	1,120	-
有利子負債 Interest-bearing debt	335,070	335,374	393,100	393,100	386,127	394,794	389,798	352,735	-
純有利子負債 Net debt	166,357	141,939	118,010	118,010	83,555	108,382	134,033	176,987	-
自己資本比率 Equity ratio	35.0%	37.6%	37.1%	37.1%	37.6%	40.5%	43.3%	43.4%	-

4. 連結キャッシュ・フロー計算書 / Consolidated statement of cash flows

百万円 (¥ million)

項目 Item	FY2022							FY2023						
	Q1	Q2	Q2 Total	Q3	Q3 Total	Q4	Total	Q1	Q2	Q2 Total	Q3	Q3 Total	Q4	Total
営業キャッシュ・フロー Cash flows from operating activities	-	-	68,833	46,423	115,256	54,473	169,729	-	-	6,307	48,636	54,943	-	-
投資キャッシュ・フロー Cash flows from investing activities	-	-	-50,453	-6,671	-57,124	-13,892	-71,016	-	-	-15,653	-22,207	-37,860	-	-
フリー・キャッシュ・フロー Free cash flows	-	-	18,380	39,752	58,132	40,581	98,713	-	-	-9,346	26,429	17,083	-	-
財務キャッシュ・フロー Cash flows from financing activities	-	-	-44,078	34,765	-9,313	-31,354	-40,667	-	-	-35,452	-76,982	-112,434	-	-

* FY2023Q2より科学事業を非継続事業に分類したことに伴い、FY2022Q3、Q3 total、Q4、totalの数値も組み替えて表示しています。FY2022Q4、totalの数値は監査前の数値となります。
From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2022Q3, Q3 total, Q4 and total.
The figures for the FY2022Q4 and total are before the audit.

なお、非継続事業からのキャッシュ・フローは以下の通り / Cash flows from discontinued operation are as below.

百万円 (¥ million)

項目 Item	FY2022							FY2023						
	Q1	Q2	Q2 Total	Q3	Q3 Total	Q4	Total	Q1	Q2	Q2 Total	Q3	Q3 Total	Q4	Total
営業キャッシュ・フロー Cash flows from operating activities	-	-	5,144	1,628	6,772	-	-	-	-	-10,958	-2,693	-13,651	-	-
投資キャッシュ・フロー Cash flows from investing activities	-	-	-2,916	-1,681	-4,597	-	-	-	-	-6,017	-2,195	-8,212	-	-
財務キャッシュ・フロー Cash flows from financing activities	-	-	-380	-285	-665	-	-	-	-	-1,039	-327	-1,366	-	-

5. 従業員数 / Number of employees

項目 Item	FY2022		FY2023		FY2023		FY2023		FY2023	
	As of Mar 31		As of Jun 30		As of Sep 30		As of Dec 31		As of Mar 31	
合計 (非継続事業含む) Total (Including discontinued operation)	31,557	(18,700)	32,177	32,177	(19,208)	32,357	(19,427)	32,401	(19,499)	-
内視鏡事業 Endoscopic Solutions Division	13,646	(7,387)	13,946	13,946	(7,453)	14,031	(7,568)	14,032	(7,589)	-
治療機器事業 Therapeutic Solutions Division	8,252	(5,725)	8,309	8,309	(5,855)	8,276	(5,842)	8,290	(5,875)	-
医療分野 Medical Business	21,898	(13,112)	22,255	22,255	(13,308)	22,307	(13,410)	22,322	(13,464)	-
その他、全社 Others, Corporate	5,950	(3,337)	5,843	5,843	(3,404)	5,890	(3,394)	5,895	(3,417)	-
非継続事業 Discontinued Operation	3,709	(2,251)	4,079	4,079	(2,496)	4,160	(2,623)	4,184	(2,618)	-

* 上表の従業員数は正社員のみでパートは含まれておりません。 / The number of temporary employees is not included in the number of employees.

* () は海外従業員数です。 / () : Number of overseas employees

* FY2023 6月30日時点の非継続事業の従業員数に誤りがあったため、数値を遡及して修正しています。 /

Due to an error in the number of employees in discontinued operation as of June 30, FY2023, the figures have been retroactively revised.

6. 会社概要 / Corporate Outline

■会社概要 / Corporate outline

2022年9月30日現在
As of Sep 30, 2022

会社名	オリンパス株式会社
Company name	Olympus Corporation
上場市場	東京証券取引所プライム市場
Market	Prime Market
銘柄コード	7733
Stock code	ISIN: JP3201200007
設立年月日	1919年10月12日
Established	October 12, 1919
資本金（百万円）	124,643
Capital (¥ million)	
グループ会社数	104（本社除く / excluding Olympus Corporation）
Number of group companies	
本社	〒163-0914 東京都新宿区西新宿2丁目3番1号 新宿モリス
Head Office	https://www.olympus.co.jp/ Shinjuku Monolith, 3-1 Nishi-Shinjuku 2-chome, Shinjuku-ku, Tokyo 163-0914, Japan https://www.olympus-global.com/network/
事業場	八王子市（東京都）、上伊那郡（長野県）、西白河郡（福島県）
Factory, R&D Center	Hachioji Tokyo Met., Kami Ina Nagano Pref., Nishi Shirakawa Fukushima Pref.
支店	札幌、名古屋、大阪、広島、福岡、神戸
Branch Offices	Sapporo, Nagoya, Osaka, Hiroshima, Fukuoka, Kobe
営業所	新潟、松本、静岡、金沢、京都、岡山、松山、鹿児島
Sales Offices	Niigata, Matsumoto, Shizuoka, Kanazawa, Kyoto, Okayama, Matsuyama, Kagoshima
海外拠点	アメリカ、ドイツ、イギリス、中国、シンガポールほか
Overseas Offices	USA, Germany, UK, China, Singapore etc

■株式状況 / Stock information

2022年9月30日現在
As of Sep 30, 2022

発行可能株式総数（株）	4,000,000,000
Total Number of Authorized Shares	
発行済株式総数（株）	1,285,892,000
Number of Shares Issued (Shares)	

■株式の分布状況 / Shareholder Distribution

2022年9月30日現在
As of Sep 30, 2022

	所有株式数 Number of shares	所有株式数の割合 Shareholders ratio
金融機関	467,084,972	36.3%
Japanese financial institution		
証券会社	4,709,267	0.4%
Japanese securities firms		
その他国内法人	28,900,014	2.2%
Other Japanese corporations		
外国人	720,690,226	56.0%
Foreign institutions and individuals		
個人・その他	51,766,539	4.0%
Japanese individuals and others		
自己株式	12,740,982	1.0%
Treasury stock		
合計	1,285,892,000	100.0%
Total		